Skip to main content

Search UC San Diego Today

Keyword is required

Your search for “Lung Infection” returned 80 results

Rethinking Remdesivir

UC San Diego researchers modify remdesivir, creating oral version that can be taken earlier in COVID-19 diagnoses. In cell and animal studies, revised drug proved effective and safe.

E-Cigarette Vapor Boosts Superbugs and Dampens Immune System

Researchers at the University of California, San Diego School of Medicine and Veterans Affairs San Diego Healthcare System report data suggesting that e-cigarettes are toxic to human airway cells, suppress immune defenses and alter inflammation, while at the same time boosting bacterial virulence. The mouse study is published January 25…

What Elephant Seals Can Tell Us About Using Carbon Monoxide to Heal

In a new study, most marine mammals were found to exhale carbon monoxide at levels equivalent to or greater than the amount exhaled by a several-packs-a-day smoker.

Nanosponges Could Intercept Coronavirus Infection

Nanoparticles cloaked in human lung cell membranes and human immune cell membranes can attract and neutralize the SARS-CoV-2 virus in cell culture, causing the virus to lose its ability to hijack host cells and reproduce.

Statins Reduce COVID-19 Severity, Likely by Removing Cholesterol That Virus Uses to Infect

Analyzing anonymized patient medical records, UC San Diego researchers discovered that cholesterol-lowering statins reduced risk of severe COVID-19 infection, while lab experiments uncovered a cellular mechanism that helps explain why.

Computational Models Move Researchers Closer to Tuberculosis Vaccine

According to a 2021 World Health Organization report, the global COVID-19 pandemic caused an increase in tuberculosis (TB) deaths – 1.5 million in 2020 versus 1.4 million in 2019 – due to a lack of efficient diagnosis and treatment.

UC San Diego Health Joins International Clinical Trial to Test Coronavirus Vaccine

UC San Diego Health will be a test site for a third, major Phase III clinical trial to assess a vaccine candidate for the novel coronavirus that causes COVID-19. Sponsored by Janssen Pharmaceuticals, the trial will recruit up to 60,000 participants at sites in the United States and worldwide.

Researchers Find a Likely Cause of Inflammatory Myofibroblastic Tumors

Researchers at University of California San Diego School of Medicine have found that a likely cause of inflammatory myofibroblastic tumors is deficiency in nonsense-mediated RNA decay (NMD), a system cells use to control which genes are activated.

Loss of Smell Associated with Milder Clinical Course in COVID-19

Researchers at UC San Diego Health report in newly published findings that olfactory impairment suggests the resulting COVID-19 disease is more likely to be mild to moderate, a potential early indicator that could help health care providers determine which patients may require hospitalization.

Common Medication Used to Reduce Cholesterol Levels May Reduce COVID-19 Severity 

Using anonymized medical records from a national registry, UC San Diego researchers confirm earlier findings that statins may substantially minimize adverse outcomes from SARS-CoV-2 infection.